 | |
| Clinical data | |
|---|---|
| Other names | 5-APDI; 1-(5-Indanyl)-2-aminopropane; Indanylaminopropane; IAP; Indanametamine; 2-Aminopropylindane; 2-API; Indanylamphetamine |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H17N |
| Molar mass | 175.275 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
5-(2-Aminopropyl)-2,3-dihydro-1H-indene (5-APDI), also known asindanylaminopropane (IAP),2-aminopropylindane (2-API),indanametamine, and, incorrectly, asindanylamphetamine,[1] is anentactogen andpsychedelicdrug of theamphetamine family.[2][3] It has been sold byonline vendors through theInternet and has been encountered as adesigner drug since 2003,[1] but its popularity and availability has diminished in recent years.
5-APDI appears to act as apotent and weaklyselectiveserotonin releasing agent (SSRA) withIC50 values of 82 nM, 1,848 nM, and 849 nM for inhibiting thereuptake ofserotonin,dopamine, andnorepinephrine, respectively.[2][3] It fully substitutes forMBDB but notamphetamine in trained animals, though it does produce disruption for the latter at high doses.[2]
5-APDI has been classified as a class B drug under the Misuse of Drugs Act 1971 since 10 June 2014.
The fusion of 5-APDI with3,3-Diphenylpropylamine was reported in a 1968 patent.[4] The dose (of the HCl salt) was judged to be 55mg per tablet (corr. to 50mg of the Fb). The compound had valuable pharmacodynamic properties whilst it's toxicity was low. It produces a vasodilatation and thus improves peripheral blood circulation and a pronounced coronary dilatation. The compound further exhibits a blood pressure lowering effect and is therefore indicated for use in the treatment of hypertonia and circulatory illnesses, especially Angina pectoris and other stenocardiac disorders and in the treatment of organic or functional coronary insufficiencies and peripheral blood circulation disorders.
